LIVE EVENT: The U.S. healthcare law rollout: Where do we stand?
ZURICH - An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said on Friday.
NEW YORK (Reuters Health) - It's never too late to start exercising, according to a new study that found formerly inactive seniors who took up exercise still experienced health benefits.
- An experimental drug for ulcerative colitis and Crohn's disease from Takeda Pharmaceutical Co could pose risk of a potentially fatal brain infection called PML even though the problem has not been seen in clinical trials, staff members of the U.S. Food and Drug Administration said on Thursday.
COPENHAGEN - Danish healthcare products maker Coloplast aims for another year of double-digit sales growth in the United States, its chief financial officer told Reuters on Friday.
LONDON - European regulators have started an in-depth review of the benefits and risks of Ariad Pharmaceuticals Inc's leukaemia medicine Iclusig.
LONDON - Researchers cast doubt on the prevailing wisdom that vitamin D supplements can prevent conditions like cancer, diabetes and heart disease, saying on Friday low vitamin D may be a consequence, not a cause, of ill health.
LONDON - British drugmaker Shire, whose shares have stormed ahead this year, disappointed investors on Friday with clinical trial results of a new dry eye drug that left the product's future unclear.
NEW YORK (Reuters Health) - Women who were exposed to air pollution during pregnancy tended to give birth to slightly lighter babies, in a new study from New York City.
NEW YORK - U.S. prosecutors have charged 49 current and former Russian diplomats and their family members with participating in a scheme to get health benefits intended for the poor by lying about their income.
NEW YORK (Reuters Health) - People with rheumatoid arthritis are better off than they were 20 years ago, according to new research from the Netherlands.
On Wednesday, December 4 at 10:30 a.m. watch live as experts assess where the U.S. stands in the healthcare law rollout and the resulting health policy implications. Presented by the forum at Harvard School of Public Health in collaboration with Reuters. Live Coverage